MétaCan
Menu
Back to cohort

DI-037 Comparison of indirect treatment for first-line metastatic pancreatic cancer: Abstract DI-037 Table 1

2014· article· en· W2314059412 on OpenAlexaboutno aff
MJ Gandara-Ladronde Guevara, JF López-Vallejo, C Palomo-Palomo, MA Blanco-Castaño, JC Garciadeparedes-Esteban, S Fénix-Caballero, JM Borrero-Rubio, J Diaz-Navarro, E Ríos-Sánchez

Bibliographic record

VenueEuropean Journal of Hospital Pharmacy · 2014
Typearticle
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsnot available
Fundersnot available
KeywordsFOLFIRINOXGemcitabineMedicineErlotinibOncologyInternal medicinePancreatic cancerPopulationHazard ratioOxaliplatinConfidence intervalCancerEpidermal growth factor receptorColorectal cancer

Abstract

fetched live from OpenAlex

<h3>Background</h3> There have been no head to head clinical trials to compare the main alternatives available to first line metastatic pancreatic cancer (mPC). <h3>Purpose</h3> To assess the relative effectiveness of treatments that have demonstrably increased overall survival in mPC <h3>Materials and methods</h3> A search was performed in PubMed and selected Phase III trials with overall survival data in first-line mPC and drugs approved by the FDA or EMEA. Similarity among trials was assessed according patient selection criteria, study population and control group results. The effectiveness outcome selected was overall survival. A therapeutic equivalence interval was established: 0.75 to 1.33 using hazard ratio (HR) obtained for sample calculation of erlotinib/gemcitabine study. Therapeutic equivalence of treatments was determined according to a previous guideline for positioning of equivalent therapeutic alternative. Grades 3 or 4 neutropenia data were used to assess relative safety. Bucher’s method was used to adjust the therapeutic comparison and the application developed by the Canadian Agency for Drugs and Technologies in Health (CADTH) to compare treatment indirectly (ITC). <h3>Results</h3> Three trials were selected: FOLFIRINOX, Albumin-bound paclitaxel (Nab) paclitaxel/gemcitabine and erlotinib/gemcitabine treatments compared with gemcitabine alone. They were similar for patient-selection criteria, study population and control group results. The results are summarised in the table: OS: overall survival HR: hazard ratio <h3>Conclusions</h3> FOLFIRINOX was more effective than erlotinib/gemcitabine. Erlotinib/gemcitabine and Nab-paclitaxel/gemcitabine are not therapeutically equivalent to FOLFIRINOX. FOLFIRINOX resulted in less grade 3/4 neutropenia than Nab-paclitaxel/gemcitabine. No conflict of interest.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.243
Threshold uncertainty score0.821

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.086
GPT teacher head0.406
Teacher spread0.320 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of Hospital PharmacySame topicPancreatic and Hepatic Oncology ResearchFrench-language works237,207